Scn1A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The SCN1A gene encodes the voltage-gated sodium channel Nav1.1, critical for neuronal excitability and implicated in epilepsy and Dravet syndrome.
| Property |
Value |
| Gene Symbol |
SCN1A |
| Full Name |
Sodium Voltage-Gated Channel Alpha Subunit 1 |
| Chromosomal Location |
2q24.3 |
| NCBI Gene ID |
6335 |
| OMIM |
182389 |
| Ensembl ID |
ENSG00000144285 |
| UniProt |
P35498 |
SCN1A encodes Nav1.1, a voltage-gated sodium channel alpha subunit essential for:
- Action potential initiation and propagation
- Sodium influx during depolarization
- Fast-spiking interneuron function
- Cortical excitation-inhibition balance
Nav1.1 is particularly important in inhibitory interneurons.
SCN1A loss-of-function mutations cause Dravet syndrome, a severe developmental and epileptic encephalopathy[1].
- Generalized epilepsy with febrile seizures plus (GEFS+)
- Intractable childhood epilepsy with focal seizures
- Lennox-Gastaut syndrome (some cases)
- Migraine (familial hemiplegic migraine type 3)
- Ataxia
SCN1A is expressed in:
- Cortical pyramidal neurons
- Hippocampal neurons
- Cerebellar Purkinje cells
- Peripheral neurons
| Drug |
Target |
Status |
| Fenfluramine |
Serotonin (also affects sodium channels) |
Approved for Dravet |
| Stiripentol |
GABA-A receptor + sodium channels |
Approved for Dravet |
| Cannabidiol |
Multiple (including sodium channels) |
Approved for epilepsy |
- Alpha subunit: 2,016 amino acids, ~260 kDa
- Four domains (I-IV), each with 6 transmembrane segments
- Voltage sensor: S4 segment detects membrane depolarization
- Activation gate: Domain IV S6 segment
- Inactivation gate: Cytoplasmic loop between domains III and IV
- Fast inactivation: IP3-mediated ball-and-chain mechanism
- Recovery from inactivation: Critical for high-frequency firing
- Persistent current: Small non-inactivating component
- Resurgent current: Special feature enabling burst firing
- Scn1a knockout: Severe seizures, early death
- Scn1a heterozygous: Model for Dravet syndrome
- Mutation knock-in: GOF and LOF models
- Interneuron dysfunction is primary mechanism
- Selective loss of fast-spiking interneurons
- Therapeutic rescue possible in juvenile mice
- Genetic modifiers influence phenotype severity
- AAV vectors: Delivering functional SCN1A
- Antisense oligonucleotides: Reducing toxic splice variants
- CRISPR editing: Correcting mutations
- EEG patterns: Biomarker for treatment response
- iPSC models: Patient-derived neurons for testing
- Behavioral assays: Seizure frequency monitoring
- Nav1.1 downregulation in AD brain
- Excitotoxicity contribution
- Beta-amyloid effects on sodium channels
- Channel dysregulation in dopaminergic neurons
- Potential therapeutic target
- Motor neuron excitability altered
- Sodium channelopathies in ALS models
The study of Scn1A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Last updated: 2026-03-04